Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 8/20 | 0.39 |
| ▸ | BRD4 | O60885 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 3/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.31 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19710938 | 0.87 | MEN1 (0.39) | CREBBPBRD4PTGS2 | |
| SCHEMBL22479536 | 0.85 | HDAC4 (0.39) | CREBBPBRD4HSD11B1 | |
| SCHEMBL21859183 | 0.79 | CREBBP (0.40) | CREBBPBRD4BMPR1BBMPR1AACVRL1 | |
| SCHEMBL22862951 | 0.78 | CREBBP (0.34) | CREBBPBRD4 | |
| SCHEMBL2625533 | 0.77 | MEN1 (0.41) | CREBBPBRD4DPP4DPP7PTGS2 | |
| SCHEMBL21164449 | 0.76 | HDAC8 (0.42) | CREBBPBRD4HSD11B1 | |
| SCHEMBL23718902 | 0.75 | CREBBP (0.35) | CREBBPBRD4POLBDPP4DPP7 | |
| SCHEMBL21099411 | 0.75 | NR1I2 (0.43) | CREBBPBRD4HSD11B1 | |
| SCHEMBL9746668 | 0.73 | RIPK1 (0.43) | — | |
| SCHEMBL18713511 | 0.72 | CREBBP (0.46) | CREBBPBRD4DPP4DPP7HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192666-A1 | PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-06-22 | — | — | US | disclosed |
| US-11028079-B2 | Small molecule BET bromodomain inhibitors and uses thereof | CONVERGENE, LLC (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200223836-A1 | SMALL MOLECULE BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC | 2020-07-16 | — | — | US | disclosed |
| US-9878997-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9809590-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170217936-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028079-B2 | Small molecule BET bromodomain inhibitors and uses thereof | BRDT, BRD4, BRD3 | CREBBP 21/4885BRD4 2/4885POLB 195/4885 |
| US-20200223836-A1 | SMALL MOLECULE BET BROMODOMAIN INHIBITORS AND USES THEREOF | BRDT, BRD4, BRD3 | CREBBP 21/4885BRD4 2/4885POLB 195/4885 |
| US-20230192666-A1 | PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, NR5A2 | CREBBP 692/4885BRD4 1066/4885POLB 3855/4885 |
| US-20170217936-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | RET, TK1, DSTYK | CREBBP 807/4885BRD4 2222/4885POLB 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.